Mylan Launches First Equivalent Product to Lexapro® YES!

The first equivalent to Lexapro® (escitalopram

oxalate) is now available
For your patients currently on Lexapro® and those you are considering for Lexapro®:
Now you can offer them the same quality treatment at a lower price
Escitalopram Tablets USP is approved as a safe and effective acute and maintenance treatment for major depressive disorder (MDD) in adults and adolescents (aged 12-17 years) and for the acute treatment of generalized anxiety disorder (GAD) in adults.

 I think you should consider taking some investment tips in MYLAN  Nasdaq stocks (MYL) 😉

Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Escitalopram Tablets USP, 5 mg, 10 mg and 20 mg, the first equivalent product to Forest Laboratories’ Lexapro®, which is used for acute and maintenance treatment of major depressive disorder (MDD) and acute treatment of generalized anxiety disorder (GAD).

Mylan will market this product exclusively until the expiration of the pediatric exclusivity on the compound patent, as per the settlement agreement between Mylan’s Alphapharmsubsidiary and Forest Laboratories Inc.

  “Mylan CEO Heather Bresch said:We are extremely pleased to be the first company to offer the first equivalent product to Lexapro, allowing customers, payors and patients to realize significant savings from our high quality, more affordable treatment option.”

Lexapro had U.S. sales of approximately $2.9 billion for the 12 months ending Dec. 31, 2011, according to IMS Health.

Currently, Mylan has 172 ANDAs pending FDA approval representing $98.1 billion in annual sales, according to IMS Health. Forty-one of these pending ANDAs are potential first-to-file opportunities, representing $26.1 billion in annual brand sales, for the 12 months ending June 30, 2011, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry’s broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world’s largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on allergy, respiratory and psychiatric therapies. For more information about Mylan, please visit For more information about generic drugs, please visit

What do you think ?

Please log in using one of these methods to post your comment: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: